Trial Profile

Phase II, open-label, not comparative, multicenter study of multiple doses of NEPA (Netupitant+Palonosetron) in preventing chemotherapy induced nausea and vomiting (CINV) in patient with Non Hodgkin's Lymphoma receiving salvage chemotherapy followed by high dose chemotherapy and autologous hematopoietic stem cells support

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 18 Jan 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

01 Feb 2022 Results published in the Supportive Care in Cancer
11 Oct 2021 New source identified and integrated (European Clinical Trials Database: EudraCT2015-003318-26).
04 May 2020 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com